enGene Therapeutics Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
enGene Therapeutics Inc. (ENGN) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of -0.60% for the 12-month period ending 2025-10-31, per its 10-K filed 2025-12-22.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2025-12-22
- enGene Therapeutics Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2025 was -0.60%.
- enGene Therapeutics Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was -1.07%, a 663.16% decline from fiscal 2023.
- enGene Therapeutics Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was 0.19%, a 34.48% decline from fiscal 2022.
- enGene Therapeutics Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was 0.29%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2025-10-31 | -0.60% 10-K · filed 2025-12-22 | |
| 2024-10-31 | -1.07% 10-K · filed 2025-12-22 | 1.07% 10-K · filed 2024-12-19 |
| 2023-10-31 | 0.19% 10-K · filed 2024-12-19 | |
| 2022-10-31 | 0.29% 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |